Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK2 | P53671 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | YAP1 | P46937 | 3/20 | 0.50 |
| ▸ | STS | P08842 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19123127 | 0.94 | JAK2 (0.53) | LIMK2KDM4EPKMYAP1STS | |
| SCHEMBL21997461 | 0.90 | KDM4E (0.52) | LIMK2KDM4EPKMYAP1STS | |
| SCHEMBL28830506 | 0.90 | KDM4E (0.54) | LIMK2KDM4EPKMYAP1STS | |
| SCHEMBL1240761 | 0.86 | KDM4E (0.50) | LIMK2KDM4EPKMYAP1STS | |
| SCHEMBL19063601 | 0.85 | JAK2 (0.52) | LIMK2KDM4EPKMYAP1STS | |
| SCHEMBL803663 | 0.84 | JAK2 (0.54) | KDM4EPKMSTSJAK2JAK1 | |
| SCHEMBL27140943 | 0.84 | SMN1; SMN2 (0.52) | LIMK2KDM4EPKMYAP1STS | |
| SCHEMBL31697910 | 0.84 | SMN1; SMN2 (0.52) | LIMK2KDM4EPKMYAP1STS | |
| SCHEMBL25292448 | 0.82 | SIGMAR1 (0.51) | SMN1; SMN2NPC1RAB9AL3MBTL1KMT2A | |
| SCHEMBL9546474 | 0.82 | CCR1 (0.54) | LIMK2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053078-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1289954-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6900196-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040259868-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-12-23 | — | — | US | disclosed |
| US-20030109706-A1 | Serine pretease inhibitors | ELI LILLY AND COMPANY | 2003-06-12 | — | — | US | disclosed |
| EP-1289954-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096303-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| WO-1993023373-A1 | N-[N'-(5-AMINO-4-HYDROXY-ACYLOYL)-α-AMINOACYLOYL] SUBSTITUTED HETEROCYCLES AND THEIR USE AS ANTIVIRAL AGENTS | PFIZER LIMITED (GB) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109706-A1 | Serine pretease inhibitors | PRSS1, SERPINE1, HPN | LIMK2 1820/4885KDM4E 2936/4885PKM 1204/4885 |
| US-20040259868-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | LIMK2 1540/4885KDM4E 3503/4885PKM 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.